PubMed Health⌕ Search

Biomedical subjects

I Marcus

Publications and source records attributed to I Marcus.

31 records · Page 2Linked to original sources
PubMed1975

[Tolerance and immunogenicity of an attenuated live influenza virus vaccine in man (author's transl)].

The attenuated influenza-A-virus strain "Alice" (H3N2) - A Recombination from A2/England/72 and A/PR8 Mount Sinai/34 - was given intransally in drops (10(7,2) ID50 per dose), twice seven days apart. In a similar fashion, 25 healthy persons received placebos. Local antibodies were determined before and three weeks after the first vaccination from nasal irrigation fluid. The fluid was concentrated and adjusted to an IgA amount of 50 mg/l. Blood samples were obtained at similar intervals. Systemic antibody formation was comparable to that obtained with inactivated virus vaccine. There was good antibody formation against retrospective and prospective virus strains of the actual drift period. The conversion rate of antineuraminidase antibodies was comparable to that obtained with inactivated virus vaccine. The locally induced antibodies behaved predominantly in a strain-specific manner. However, there were also reactions with the virus strains Port Chalmers and Hong Kong. Live vaccine should in future be used in "drift" times, while inactivated virus vaccine should be used in shift periods (occurrence of new virus strains).

Administration, Intranasal↗
PubMedDate not supplied

Post-exposure use of human diploid cell culture rabies vaccine.

880 individuals, 120 of which were exposed to rabid animals, were immunized pre- or post-exposure with 2 different BPL-inactivated and concentrated rabies vaccines prepared in HDC strains WI-38 and MRC-5. The vaccines were well tolerated and no major side effects were observed after primary immunization with 3-10 doses or 1 booster vaccination. The dynamics of neutralizing, antibody formation and persistence of antibodies in 4 different groups of vaccinees are described. The groups were vaccinated pre-exposure (I) on days 0, 28 and 56; (II) on days 0, 7 and 14; (III) on days 0, 3, 7 and 21; and (IV) post-exposure on days 0, 3, 7, 14, 30 and 90. High antibody levels--persisting for at least 30 months--were obtained in all patients. The CFT, using a concentrated and purified virion antigen, was highly specific for rabies virus antibody demonstration. Since in some 50 patients under severe risk, after having been bitten and/or scratched by proven rabid animals, not a single breakthough of immunity was observed during an observation time between 1/2 and 3 years, the protective effect of the HDCS-rabies vaccines seems to be excellent. With regard to their high immunogenicity and extremely low reactogenicity, the new HDCS-vaccines can be recommended for prophylactic and post-exposure immunization of man without any reserve. Data on simultaneous application of homologous anti-rabies gammaglobulin from man (20 I.E./kg body-weight) and HDCS-vaccines are also presented and discussed.

Adolescent↗